The health care industry is viewed as a defensive sector and as a hedge during market uncertainty. Today we look for quality U.S.-listed companies in that sector. To do that, we screened the U.S. health care universe, including American depositary receipts, by focusing on the following criteria:
Signals indicating a nearing bear market have been encircling us for months. In periods such as these, fundamental analysis is key; we’re looking for real quality that can protect one’s portfolio. With U.S. technology stocks taking a particularly big hit recently, I decided to make that sector our focus. We screened the U.S. information technology sector by focusing on the following criteria:
- Positive 12-month change in the economic value-added (EVA) metric – a positive figure shows us that the company’s profits are increasing at a faster and greater pace than the costs of capital. The EVA gives us a sense of how much value this stock is adding for shareholders and is calculated by taking the net operating profit after tax and subtracting the capital expense;
- Positive EVA/share, and EVA/share growth over 12 months;
- Economic performance index (EPI) – the ratio of return on capital to cost of capital – must be greater than one;
- Average five-year return on capital must be greater than 10 per cent and the 12-month change in return on capital must be positive;
- Future growth value/market value (FGV/MV) and its 12-month change. This ratio represents the proportion of the market value of the company that is made up of future growth expectations rather than the actual profit generated. The higher the percentage, the higher the baked-in premium for expected growth and the higher the risk;
- Beta – this gives us an idea of how closely the company mimics the market’s fluctuations. A beta of less than one would indicate the stock is less volatile than the market at large.
- A 12-month change in current operating value equal to or greater than zero. Current operating value represents the real profits of the company and is calculated by the net operating profit after tax (NOPAT) divided by the cost of capital – this allows us to better compare companies with varying costs and of different sizes;
- A positive change in the 12-month NOPAT – a measure of operating efficiency that excludes the cost and tax benefits of debt financing by simply focusing on the company’s core operations net of taxes;
- Rising earnings per share over a 12-month period;
- Future growth value/market value (FGV/MV) between minus 50 and 50, to exclude companies with exaggerated discounts or premiums. FGV/MV represents the proportion of the market value of the company that is made up of future growth expectations rather than the actual profit generated. The higher the percentage, the higher the baked-in premium for expected growth and the higher the risk.